GSA Capital Partners LLP Increases Holdings in Kodiak Sciences Inc. (NASDAQ:KOD)

Key Points

• GSA Capital Partners LLP significantly increased its stake in Kodiak Sciences by 163.6%, owning 205,833 shares after acquiring an additional 127,748 shares during the first quarter.
• Kodiak Sciences reported a quarterly earnings loss of $1.09 per share, missing the consensus estimate by $0.20.
• The company is currently focused on developing therapies for retinal diseases, with its lead product candidate in advanced clinical trials for conditions such as wet age-related macular degeneration.

GSA Capital Partners LLP increased its position in shares of Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 163.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 205,833 shares of the company's stock after purchasing an additional 127,748 shares during the period. GSA Capital Partners LLP owned about 0.39% of Kodiak Sciences worth $577,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of KOD. Price T Rowe Associates Inc. MD increased its holdings in Kodiak Sciences by 10,982.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,268,509 shares of the company's stock valued at $12,622,000 after purchasing an additional 1,257,063 shares during the last quarter. TCG Crossover Management LLC raised its stake in Kodiak Sciences by 13.6% in the fourth quarter. TCG Crossover Management LLC now owns 1,145,538 shares of the company's stock valued at $11,398,000 after buying an additional 137,380 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in shares of Kodiak Sciences during the fourth quarter worth approximately $11,338,000. Silverarc Capital Management LLC increased its stake in shares of Kodiak Sciences by 100.0% during the fourth quarter. Silverarc Capital Management LLC now owns 1,000,000 shares of the company's stock worth $9,950,000 after purchasing an additional 500,000 shares during the period. Finally, Boxer Capital Management LLC bought a new position in Kodiak Sciences during the 4th quarter worth $9,950,000. 89.06% of the stock is currently owned by institutional investors.

Kodiak Sciences Price Performance

Shares of NASDAQ KOD traded down $0.02 during mid-day trading on Thursday, hitting $8.19. 201,501 shares of the stock traded hands, compared to its average volume of 420,076. The company has a market cap of $432.14 million, a PE ratio of -2.25 and a beta of 2.41. Kodiak Sciences Inc. has a twelve month low of $1.92 and a twelve month high of $11.60. The firm has a 50 day simple moving average of $4.87 and a two-hundred day simple moving average of $4.39.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.20). On average, equities research analysts anticipate that Kodiak Sciences Inc. will post -3.45 earnings per share for the current fiscal year.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.